This site contains promotional information intended only for healthcare professionals resident in the United Kingdom
Information on how to access prescribing information and adverse event reporting can be found at the bottom of the page.
When developing an AFS programme, published guidelines can support the creation of your own local recommendations. Guidelines can be used to support prescribing decisions but Cresemba® (isavuconazole) should always be prescribed within its licenced indication.
Cresemba® (isavuconazole) is indicated in adults for the treatment of invasive aspergillosis, and of mucormycosis in patients for whom amphotericin B is inappropriate.1
Consideration should be given to official guidance of the appropriate use of antifungals.1
|Guidelines||Population||Recommended treatments||Preferred alternative treatments|
|ECIL-6 (2017)2||Leukaemia and HSCT patients||Voriconazole (A I)
|Liposomal amphotericin B
Amphotericin B lipid complex
|Liposomal amphotericin B (B II)|
|Infection resistant to amphotericin B (MIC ≥1 mg/L)||Voriconazole
|A. terreus infection||Voriconazole
|Posaconazole (B III)
Itraconazole (B III)
|First-line monotherapy||Salvage therapy after first-line amphotericin B|
|All patients||Liposomal amphotericin B (A II)||Patients with refractory disease||Isavuconazole (A II)|
|Isavuconazole (B II)||Posaconazole DR tablet (A II)|
|Posaconazole DR tablet or IV (B II); oral suspension (C II)||Posaconazole oral suspension (C II)
Amphotericin B liposomal (A II); lipid complex (B II)
|Amphotericin B deoxycholate (D II)|
with CNS involvement
|Lipsomal amphotericin B (A III)|
|Patients without CNS involvement||Amphotericin B lipid complex (B II)||Patients with toxicity or intolerance to first-line treatment||Isavuconazole (A II)|
|Patients with pre-existing renal compromise||Isavuconazole||Posaconazole DR tablet (A II)|
|Posaconazole||Posaconazole; oral suspension (C II)
Amphotericin B liposomal (A II); lipid complex (B II)
|SOT recipients||Amphotericin B lipid formulation (A II) or amphotericin B lipid complex (A II)|
|Haematological malignancies||Liposomal amphotericin B (C III)|
|Orbital mucormycosis||Retrobulbar injection of amphotericin B deoxycholate in addition to systemic therapy (D III)|
CRESEMBA® is highly recommended for the treatment of invasive aspergillosis by the latest guidelines, including ECIL-6 and ESCCMID.2-4
a. Strength of recommendation - A: Good evidence to support recommendation (ECIL-6) Strongly supported (ESCMID-ECMM-ERS); B: Moderate evidence to support recommendation (ECIL-6) Moderately supported (ESCMID-ECMM-ERS); C: Poor evidence to support recommendation (ECIL-6) Marginally supported (ESCMID-ECMM-ERS); D: NA (ECIL-6) Recommendation against use (ESCMID-ECMM-ERS). Strong recommendation: most people in this situation would want the recommended course of action and only a small proportion would not (IDSA). Quality of evidence - I: ≥1 properly designed randomised controlled trial (orientated on the primary endpoint of the trial); II: ≥1 well designed clinical trial without randomisation; cohort or case-controlled analytical studies (preferably from >1 centre); multiple time series; or dramatic results from uncontrolled experiments; III: Opinions of respected authorities based on clinical experience, descriptive case studies, or reports of expert committees.2-4
ABS, antibacterial stewardship; AFS, antifungal stewardship; AMS, antimicrobial stewardship; BSMM, British Society for Medical Mycology; CNS, central nervous system; DR, delayed release; ECIL, European Conference on Infections in Leukaemia; ECMM, European Confederation of Medical Mycology; ERS, European Respiratory Society; ESCMID, European Society of Clinical Microbiology and Infectious Diseases; EMA, European Medicines Agency; FDA, Food and Drug Administration; HSCT, haematopoietic stem cell transplantation; IDSA, Infectious Diseases Society of America; IPA, invasive pulmonary aspergillosis; IV, intravenous; MIC, minimum inhibitory concentration; NA, not available; PCR, polymerase chain reaction; SOT, solid organ transplant, TDM, therapeutic drug monitoring.
Click here for CRESEMBA® (isavuconazole) and Vfend (voriconazole) prescribing information
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search
for MHRA Yellow Card in Google Play or Apple App Store
Adverse events should also be reported to Pfizer Medical Information on 01304 616161
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc
This website is brought to you by Pfizer Limited, a company registered in England
and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ
Copyright © 2023 Pfizer Limited. All rights reserved.
VAT registration number GB201048427
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-PFE-GBR-3863. November 2021